Advertisement


Seshiru Nakazawa, MD, PhD, on NSCLC and Point Mutations as de Novo Oncogenic Drivers

IASLC 2023 WCLC

Advertisement

Seshiru Nakazawa, MD, PhD, of Dana-Farber Cancer Institute, discusses activating the MET tyrosine kinase domain mutation, which has been identified as the sole oncogenic mutation in a small but significant subset of patients with non–small cell lung cancer (NSCLC). According to Dr. Nakazawa’s findings, this mutation is potentially targetable with currently available MET tyrosine kinase inhibitors.



Related Videos

Lung Cancer
Genomics/Genetics

Xiuning Le, MD, PhD, on Update on the Use of Tepotinib to Treat an NSCLC Subset

Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results of the VISION trial, the largest on-treatment liquid biopsy biomarker data set of a MET inhibitor in patients with MET exon 14 non–small cell lung cancer (NSCLC). Tepotinib showed durable efficacy in this population.

Lung Cancer
Genomics/Genetics

Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease

Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses phase II findings from the HERTHENA-Lung01 study, which showed patients with previously treated EGFR-mutated non–small cell lung cancer may benefit from the antibody-drug conjugate patritumab deruxtecan after EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy (Abstract OA05.03). The phase III HERTHENA-Lung02 trial is ongoing.

Lung Cancer

Ilias Houda, MD, PhD Candidate, on Results of an EORTC Survey on NSCLC Resectability

Ilias Houda, MD, PhD Candidate, of Amsterdam University Medical Centers, discusses the differing opinions of thoracic surgeons when it comes to resection for stage III non–small cell lung cancer (NSCLC). The international EORTC survey showed there is no consensus, although respondents were more likely to consider some stage III TNM combinations to be potentially resectable.

Lung Cancer

Yasir Y. Elamin, MD, on Brigatinib in ALK-Rearranged Metastatic Non–Small Cell Lung Cancer

Yasir Y. Elamin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the BRIGHTSTAR study, in which brigatinib with local consolidative therapy was found to be safe in patients with ALK-rearranged advanced non–small cell lung cancer. This regimen yielded promising outcomes when compared with historical outcomes with brigatinib alone (Abstract OA22.04).

Lung Cancer

Gilberto de Lima Lopes, Jr, MD, MBA, on Lung Cancer Management: Expert Update

Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, comments on four presentations from the 2023 World Conference on Lung Cancer for which he served as discussant: the global landscape of three types of lung cancer (squamous cell, adenocarcinoma, and small cell); findings from the Australian Registry and Biobank of Thoracic Cancers; the Registry of Genetic Alterations of Taiwan by comprehensive next-generation sequencing; and treatment decisions in octogenarians with non-small cell lung cancer.

Advertisement

Advertisement




Advertisement